Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Accured Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Accured Expenses for 13 consecutive years, with $93000.0 as the latest value for Q3 2025.

  • Quarterly Change in Accured Expenses fell 70.57% to $93000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Sep 2025, down 344.05% year-over-year, with the annual reading at -$196000.0 for FY2025, 199.49% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $93000.0 at IGC Pharma, up from -$599000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $484000.0 in Q1 2023, with the low at -$599000.0 in Q2 2025.
  • Average Change in Accured Expenses over 4 years is -$3714.3, with a median of $59500.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses soared 236.17% in 2024, then plummeted 496.69% in 2025.
  • Over 4 years, Change in Accured Expenses stood at -$30000.0 in 2021, then tumbled by 793.33% to -$268000.0 in 2023, then grew by 19.4% to -$216000.0 in 2024, then soared by 143.06% to $93000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $93000.0, -$599000.0, and -$447000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.